Paterson D. Asthma: new drug targets and innovative therapeutics (London) Idrugs. 2001; 4 :646–9.Paterson D. 2001. Asthma: new drug targets and innovative therapeutics (London). Idrugs, 4:646-9.Paterson D. Asthma: new drug targets and innovative therapeutics (London) Idrugs. 2001; 4 ...
Prioritizing genes for translation to therapeutics for common diseases has been challenging. Here, we propose an approach to identify drug targets with high probability of success by focusing on genes with both gain of function (GoF) and loss of function (LoF) mutations associated with opposing eff...
therapeutics and drug design against infectious diseases using synthetic enzymology Aishwarya 被引量: 0发表: 2018年 Stapled Peptides for Intracellular Drug Targets Proteins that engage in intracellular interactions with other proteins are widely considered among the most biologically appealing yet chemically ...
Therapeutics , Targets , and Chemical Biology Cancer Research β III-Tubulin Is a Multifunctional Protein Involved in Drug Sensitivity and Tumorigenesis in... Authors' A Research South Wale Note: Sup Research O J Mccarroll,P Gan,MLM Liu,... 被引量: 0发表: 2010年 Class III beta-tubulin ove...
Drug resistance represents a significant obstacle in cancer treatment, underscoring the need for the discovery of novel therapeutic targets. Ubiquitin-specific proteases (USPs), a subclass of deubiquitinating enzymes, play a pivotal role in protein deubi
Despite considerable therapeutic advances, heart failure remains a medical and socioeconomic problem. Thus, there is a compelling need for new drugs that could improve clinical outcomes. In recent years, new potential therapeutic targets that are involved in the pathogenesis of heart failure have been...
Molecular cancer therapeutics: recent progress and targets in drug resistance. Recent progress in development of molecular cancer therapeutics revealed new types of antitumor drugs, such as Herceptin, Gleevec, and Iressa as potent the... TSURUO,Takashi - 《Internal Medicine》 被引量: 219发表: 2003...
The main outcome of another phase III clinical study (ClinicalTrials.gov; id: NCT02139306, finished in March 2017), has been announced via the PTC Therapeutics press release, and at the time of writing this review, the full data were still unpublished. The announcement reported a failure to ...
Therefore, the subtractive proteomics approach may significantly decrease the time needed to characterize prospective therapeutics targets. Our previous report revealed the relevance of the prediction of drug and vaccines candidates using the subtractive proteomics approach against ticks and tick-borne ...
Helix and Recursion join forces in quest to crack the AI-driven drug discovery code Athos Therapeutics chooses Vultr’s private cloud to power AI drug discovery engine Infectious Disease See More > Advances in next generation vaccine development for SARS-CoV-2 Typical COVID-19 vaccines present fra...